Shots:

• Novo Nordisk to acquire all outstanding shares of Dicerna common stock for $38.25/share in cash making a total equity value of ~$3.3B representing a premium of 80% to Dicerna's closing price on Nov 17, 2021. The transaction is expected to close in the Q4'21
• The acquisition will utilize Dicerna's GalXC technology platform to expand the Novo Nordisk's research within RNAi therapeutics. This acquisition supports Novo Nordisk's strategy of developing and apply a range of technology platforms across all therapeutic areas
• Novo Nordisk is expected to initiate the clinical development of RNAi therapeutic in 2022. In 2019, Novo Nordisk entered a research collaboration with Dicerna to discover and develop RNAi therapies for liver-related cardio-metabolic diseases

Ref: Novo Nordisk | Image: Dicerna